Over the past 12 months, the application of generative AI (GenAI) in the Medical Instruments industry has moved from experimental to operational use, enhancing diagnostics, patient monitoring and intervention workflows. GenAI could transform health care through synthetic medical imaging, disease progression modeling sand drug molecule design with simulated effect, according to a 2025 U.S. National Science Foundation report. At the same time, regulatory bodies are adapting. The European Union AI Act (EU AI A ...

ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 38th Annual Roth Conference. Iradimed’s CEO, Roger Susi, and CFO, Jack Glenn, will host one-on-one meetings between company management and investors at the 38th Annual Roth Conference, which will be held at the Ritz-Carlton in Laguna Niguel, CA, on March 22 and 24, 2026. About IRADIMED CORPORATION IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Im ...

Industry Overview - The U.S. medical instrument industry has stabilized entering 2026 after years of volatility due to inflation, rising interest rates, and uneven hospital spending, with procedure volumes normalizing post-pandemic [1] - Providers are cautious on capital budgets, focusing on productivity, reliability, and total cost of ownership [1] - The Medical - Instruments industry is ranked in the top 35% of the Zacks Industry Rank, indicating expected outperformance over the next three to six months [2] Company Highlights Intuitive Surgical Inc. (ISRG) - ISRG is integrating AI and digital tools into its robotic ecosystem, enhancing surgical performance metrics and providing real-time decision support [4][5] - The company has an expected revenue growth rate of 14.9% and earnings growth rate of 12.7% for the current year, with a Zacks Consensus Estimate for earnings improving by 0.5% [6] - The short-term average price target indicates a potential increase of 26% from the last closing price of $493.56, with a maximum upside of 52% [8] Globus Medical Inc. (GMED) - GMED's acquisition of Nevro and the merger with NuVasive are expected to strengthen its position in the musculoskeletal space and expand its product portfolio [9][10] - The company anticipates revenue growth of 8% and earnings growth of 7.5% for the current year, with earnings estimates improving by 6.7% [10] - The short-term average price target suggests a 24.7% increase from the last closing price of $87.81, with a maximum upside of 40.1% [11] Edwards Lifesciences Corp. (EW) - EW's Surgical Structural Heart business is benefiting from strong adoption of premium surgical technologies, with a focus on developing a comprehensive structural heart disease portfolio [12][13] - The expected revenue growth rate is 9.6% and earnings growth rate is 14.8% for the current year, with earnings estimates improving by 2.1% [14] - The short-term average price target indicates a 14% increase from the last closing price of $84.26, with a maximum upside of 30.5% [14] Alcon Inc. (ALC) - ALC is leveraging its Surgical and Vision Care segments for growth, with innovative products driving category leadership [15][16] - The expected revenue growth rate is 7.1% and earnings growth rate is 12.1% for the current year, with earnings estimates improving by 2.1% [16] - The short-term average price target suggests a 13.9% increase from the last closing price of $81.85, with a maximum upside of 36.8% [17] IRADIMED Corp. (IRMD) - IRMD specializes in MRI-compatible products and serves hospitals and outpatient imaging centers [18][19] - The expected revenue growth rate is 10.8% and earnings growth rate is 8.8% for the current year, with earnings estimates remaining stable [20] - The short-term average price target indicates a 19.9% increase from the last closing price of $100.18, with a maximum upside of 20% [20]

Regulatory Compliance - The company is subject to extensive government regulation, particularly from the FDA, which could result in delays or increased costs during product development and approval [202]. - Compliance with evolving domestic and international laws regarding AI could impose significant costs and obligations on the company [199]. - The company is subject to healthcare fraud and abuse regulations that could result in significant liability and require changes to business practices [216]. - Compliance with FDA regulations is subject to continual review and can result in sanctions, affecting sales and profitability [223]. - The FDA's guidance on infusion pumps has increased pre-market requirements, leading to higher costs and longer approval times for new products [222]. - Compliance with public company regulations may strain resources and divert management's attention from core business operations [250]. - The company is subject to evolving laws and regulations, increasing compliance costs and potentially diverting management's focus from revenue-generating activities [251]. Financial Performance and Risks - The company is exposed to risks associated with changing economic conditions, including interest rates and inflation, which could adversely affect financial results [200]. - The company carries third-party product liability insurance with a maximum coverage of $5 million, but faces significant deductibles that could impact financial condition [211]. - The company faces potential product liability claims that could materially affect profitability and financial condition [209]. - The company believes it has adequate capital for operations over the next 12 months, but may need to raise additional funds [247]. - The company may face significant fluctuations in stock price due to various factors, including product success and regulatory changes [241]. - Market fluctuations have historically impacted small capitalization medical device companies, potentially leading to declines in stock price and increased litigation risks [256]. International Operations - Sales to customers outside of the U.S. accounted for approximately 16% of net revenues in 2025, with expectations for future growth from international markets [207]. - The company operates in approximately 80 countries, with most transactions in U.S. Dollars, exposing it to foreign currency exchange risks [333]. - Fluctuations in the Japanese Yen could affect the company's net income, with a 10% change in the Yen's strength resulting in an immaterial impact on net income for the year ended December 31, 2025 [334]. Intellectual Property and Innovation - The company relies on a combination of patents and trade secrets to protect its intellectual property, but there is no guarantee these protections will be effective [226]. - Patent litigation could result in substantial expenses and may disrupt product commercialization efforts [233]. - The development and use of AI technologies present risks that could impact operations and lead to legal or regulatory challenges [198]. Corporate Governance - As of December 31, 2025, the founder owns approximately 35% of the company's outstanding common stock, allowing significant influence over stockholder approval matters [253]. - The company faces increased visibility and potential litigation risks as a public entity, which could adversely affect its business and profitability [254]. Dividends - The Board of Directors declared a quarterly cash dividend of $0.20 per share, but future dividends are not guaranteed [245].

On February 17, 2026, Nine Ten Capital Management disclosed selling 342,907 shares of IRadimed (NASDAQ:IRMD), an estimated $29.42 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Nine Ten Capital Management reduced its position in IRadimed by 342,907 shares during the fourth quarter. The estimated value of the shares sold is approximately $29.42 million, calculated using the average closing price for th ...

Core Viewpoint - Iradimed has achieved significant financial growth, setting a new all-time high in revenue for the 18th consecutive quarter, with both revenue and net income increasing at double-digit rates, leading to a nearly 10% rise in stock price on the announcement day [1]. Financial Performance - In Q4 2025, Iradimed reported revenue of $22.7 million, a 17% increase compared to Q4 2024. Net income rose 23% to just under $7 million, equating to $0.54 per share [2]. - The company exceeded consensus analyst estimates for earnings per share, which was projected at $0.48 [3]. Product Development - Iradimed's growth was bolstered by the launch of a new product, the 3870 intravenous infusion pump, which began shipping during the quarter [4]. Dividend Announcement - The company announced an increase in its quarterly dividend from $0.17 to $0.20 per share, effective March 6 for investors of record as of February 23 [5]. Future Guidance - For the full year 2026, Iradimed projects revenue between $91 million and $96 million, with non-GAAP net income expected to be between $2.06 and $2.21 per share, both significantly higher than the 2024 figures of $73 million in revenue and $1.66 per share adjusted net profit [6]. Market Position - Iradimed is positioned as a strong player in the niche medical devices segment, particularly in MRI-compatible equipment, indicating a continued growth trajectory [7].

Financial Data and Key Metrics Changes - IRadimed achieved record revenue for the 18th consecutive quarter, with Q4 2025 revenue reaching $22.7 million, a 17% increase from Q4 2024, and full-year revenue of $83.8 million, up 14% year-over-year [3][10] - GAAP diluted earnings per share for Q4 was $0.50, up 25%, and for the full year, it reached $1.75, up 17% [3][12] - Gross margins remained strong at approximately 77% for the year and 75% for Q4 [3][11] Business Line Data and Key Metrics Changes - MRI-compatible infusion pump systems contributed $9.1 million in Q4, up 20% year-over-year, while patient vital signs monitoring systems contributed $7.1 million, up 7.5% [10] - Disposable revenue grew 18% to $4.3 million, reflecting increased utilization of devices [10][11] Market Data and Key Metrics Changes - Domestic sales accounted for 81% of total revenue in Q4 and 84% for the full year, indicating strong U.S. performance [11] - There are approximately 6,400 5+-year-old 3860/3861 pump channels in the U.S. market that are up for replacement [6] Company Strategy and Development Direction - The company anticipates a significant increase in revenue from the replacement of older pump models, which is expected to be a key growth driver for the next several years [5][7] - The new 3870 MR IV pump is expected to penetrate greenfield opportunities more effectively and increase utilization among existing customers [4][5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a $100 million-plus revenue run rate during 2026, driven by the new 3870 pump and increased disposable sales [7][8] - The company plans to maintain quarterly revenue in the first half of 2026, with significant growth expected in the second half [8] Other Important Information - The company ended the year with cash and cash equivalents of $51.2 million, and cash flow from operations was $5.9 million for Q4 and $24.9 million for the full year [12] - The company is working on a next-generation MRI monitor expected to launch in 2028 [21] Q&A Session Summary Question: Initial market feedback from the pilot - Management reported very positive feedback from initial users of the 3870 pump, leading to confidence in scaling the launch [15][16] Question: Gross margin scaling - Management indicated that gross margins are expected to remain stable in the first half of the year but may improve in the second half due to higher volumes and ASP [18][19] Question: Updates on disposables and services growth - Management noted that disposable revenue growth is expected to align with capital sales, with potential for increased utilization with the new 3870 pump [26][27] Question: Inventory levels and backlog for the 3860 - Management stated that inventory levels are being closely monitored to ensure fulfillment of backlog while transitioning to the 3870 [28][29] Question: Regulatory process for 3870 in Europe and Japan - Management confirmed that CE mark approval is expected by the end of 2026, with Japan clearance anticipated by summer 2027 [32]

Financial Data and Key Metrics Changes - IRadimed achieved record revenue for the 18th consecutive quarter, with Q4 2025 revenue reaching $22.7 million, a 17% increase from Q4 2024, and full-year revenue of $83.8 million, up 14% year-over-year [3][10] - GAAP Diluted Earnings Per Share for Q4 was $0.50, up 25%, and for the full year, it reached $1.75, up 17% [3][12] - Gross margins remained strong at approximately 77% for the year and 75% for Q4 [3][11] Business Line Data and Key Metrics Changes - MRI-compatible infusion pump systems contributed $9.1 million in Q4, up 20% year-over-year, while patient vital signs monitoring systems contributed $7.1 million, up 7.5% [10] - Disposable revenue grew 18% to $4.3 million, reflecting increased utilization of devices [10][11] Market Data and Key Metrics Changes - Domestic sales accounted for 81% of total revenue in Q4 and 84% for the full year, indicating strong U.S. performance [11] - There are approximately 6,400 5+-year-old 3860/3861 pump channels in the U.S. market that are up for replacement [6] Company Strategy and Development Direction - The company anticipates a significant increase in revenue from the new 3870 MR IV pump, with an expected average selling price increase of 10%-14% [4] - The strategy includes targeting an additional 1,000 replacement sales annually from existing 5+-year-old units, aiming for a $100 million-plus revenue run rate during 2026 [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a $100 million-plus revenue run rate during 2026, driven by the new product launch and existing product sales [7][8] - The company is focused on optimizing the new 3870 pump based on initial user feedback before the broader launch [15][31] Other Important Information - Cash flow from operations was $5.9 million for Q4 and $24.9 million for the full year, with cash and cash equivalents ending at $51.2 million [12] - The company is working on a next-generation MRI monitor expected to launch in 2028 [21] Q&A Session Summary Question: Initial market feedback on the 3870 pump - Management reported very positive feedback from initial users, leading to confidence in scaling the launch [15][16] Question: Gross margin trends - Management expects gross margins to remain stable in the first half of the year, with potential improvement in the second half due to higher volumes and ASP [18][19] Question: R&D efforts post-3870 launch - The R&D team is already working on a next-generation MRI monitor, with plans for a market launch in 2028 [20][21] Question: Strength of disposables and services - Management indicated that disposable revenue growth is expected to align with capital sales, with potential for increased utilization with the new 3870 pump [26][27] Question: Inventory levels and backlog for the 3860 - Management is closely monitoring inventory levels to ensure fulfillment of backlog while transitioning to the 3870 [28][29] Question: Regulatory updates for the 3870 in Europe and Japan - Management confirmed that CE mark approval is expected by the end of 2026, with Japan clearance anticipated by summer 2027 [32]

Financial Data and Key Metrics Changes - IRadimed achieved record revenue for the 18th consecutive quarter, with Q4 2025 revenue reaching $22.7 million, a 17% increase from Q4 2024, and full-year revenue of $83.8 million, up 14% year-over-year [3][10] - GAAP Diluted Earnings Per Share for Q4 was $0.50, up 25%, while non-GAAP Diluted Earnings Per Share was $0.54, up 23% [3][12] - Gross margins remained strong at approximately 77% for the year and 75% for Q4 [3][11] Business Line Data and Key Metrics Changes - MRI-compatible infusion pump systems contributed $9.1 million, up 20% year-over-year, while patient vital signs monitoring systems contributed $7.1 million, up 7.5% [10] - Disposable revenue grew 18% to $4.3 million, reflecting increased utilization of devices [10][11] - Ferromagnetic detection systems also saw solid gains, contributing to overall revenue growth [10] Market Data and Key Metrics Changes - Domestic sales accounted for 81% of total revenue in Q4 and 84% for the full year, indicating strong U.S. market performance [11] - There are approximately 6,400 5+-year-old 3860/3861 pump channels in the U.S. market that are up for replacement, with a target of adding an additional 1,000 channels per year through replacement sales [5][6] Company Strategy and Development Direction - The company anticipates a significant increase in revenue from the large replacement opportunity, which is expected to be a key growth driver for the next several years [5][7] - The new 3870 MR IV pump is expected to penetrate greenfield opportunities more effectively and increase utilization among existing customers [4][5] - The company plans to maintain quarterly revenue in the first half of 2026, driven by growth in MRI monitoring and the 3860 pump backlog, with significant bookings expected for the 3870 systems [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a $100 million-plus revenue run rate during 2026, driven by the new 3870 pump and other product lines [7] - The initial market feedback for the 3870 pump has been very positive, with excitement from users regarding its modernized design and functionality [16][18] - The company is working on regulatory approvals for the 3870 in Europe and Japan, with expectations for CE mark by the end of 2026 and clearance in Japan by summer 2027 [33] Other Important Information - Cash and cash equivalents at year-end were $51.2 million, with cash flow from operations of $5.9 million for Q4 and $24.9 million for the full year [12] - The company is managing inventory levels closely during the transition from the 3860 to the 3870 pump [30] Q&A Session Summary Question: Initial market feedback from the pilot for the 3870 pump - Management reported very positive feedback from initial users, with additional orders already on the books [15][16] Question: Gross margin scaling expectations - Management anticipates gross margins to remain in line initially but expects improvement in the second half of the year as production ramps up [19][20] Question: Future R&D efforts post-3870 launch - The R&D team is already working on a next-generation MRI monitor, expected to launch in 2028 [22] Question: Strength of disposables and services growth - Management indicated that growth in disposables is expected to align with capital sales, with potential for increased utilization with the new 3870 pump [27][28] Question: Inventory levels and backlog for the 3860 - Management confirmed they are managing inventory levels closely and are in good shape to fulfill backlog while transitioning to the 3870 [29][30] Question: Regulatory process updates for the 3870 in Europe and Japan - Management confirmed that CE mark is expected by the end of 2026, with Japan clearance anticipated by summer 2027 [33]

Financial Performance - The Company reported record revenue of $22.7 million for Q4 2025, a 17% increase year-over-year, exceeding previous guidance [3] - For the full year 2025, the Company reported revenue of $83.8 million, a 14% increase from $73.2 million in 2024 [11] - Revenue for Q4 2025 reached $22.692 million, a 17.8% increase from $19.389 million in Q4 2024 [37] - Gross profit for the year ended December 31, 2025, was $64.324 million, up 14.1% from $56.350 million in 2024 [37] - Operating expenses for the year ended December 31, 2025, totaled $38.177 million, a 10.4% increase from $34.385 million in 2024 [37] Earnings - GAAP diluted EPS for Q4 2025 was $0.50, a 25% increase compared to Q4 2024, while non-GAAP diluted EPS was $0.54, a 23% increase [8] - Net income for Q4 2025 was $6.442 million, representing a 25.1% increase compared to $5.147 million in Q4 2024 [37] - Non-GAAP net income for Q4 2025 was $7.0 million, a 23% increase from $5.7 million in Q4 2024 [10] - Non-GAAP net income for the year ended December 31, 2025, was $24.792 million, a 16.5% increase from $21.228 million in 2024 [39] - The company reported a diluted net income per share of $0.50 for Q4 2025, compared to $0.40 for Q4 2024, marking a 25% increase [37] Cash Flow and Dividends - Cash flow from operations for Q4 2025 was $5.9 million, a slight decrease of 2% from $6.0 million in Q4 2024 [15] - Free cash flow for Q4 2025 was $5.506 million, significantly up from $2.930 million in Q4 2024 [41] - The Company declared a regular quarterly cash dividend of $0.20 per share, up from $0.17 per share, reflecting confidence in the business outlook [4] Guidance and Future Outlook - For full year 2026 guidance, the Company expects revenue between $91.0 million and $96.0 million, with GAAP diluted EPS between $1.90 and $2.05 [5] - The company anticipates meaningful revenue contributions from the next-generation 3870 MRI-compatible IV infusion pump in the future [31] Sales and Market Performance - Domestic sales accounted for 81% of total revenue in Q4 2025, down from 85% in 2024, while gross profit margin was 75% [13] - The Company shipped 3,870 units of the next-generation 3870 MRI-compatible IV infusion pump in Q4 2025, with full rollout expected in Q1 2026 [3] Assets and Equity - Total assets increased to $108.776 million in 2025, compared to $98.326 million in 2024, reflecting a growth of 10.8% [35] - Total stockholders' equity rose to $94.618 million in 2025, up from $86.819 million in 2024, indicating an increase of 9.9% [35] Stock-Based Compensation - The Company expects stock-based compensation expense to be approximately $2.0 million for the full year 2026 [18]